GRSi FedRAMP Cost: What a GRSi 3PAO Engagement Costs in 2026

GRSi is a Maryland-headquartered federal services firm that has supported civilian agencies, particularly in the health and biomedical research space, for over two decades. The firm's FedRAMP 3PAO accreditation, held through A2LA, is one component of a broader federal-services portfolio that also includes systems engineering, program management, and cybersecurity advisory work for federal clients. On the FedRAMP Marketplace assessor list GRSi sits in the upper tier of federal-services firms with active assessment books at Moderate and a smaller but growing presence at High.

The firm's heritage in HHS and biomedical research work produces meaningful agency-relationship advantages for CSPs whose sponsoring agency falls in that footprint. GRSi assessors and program leads have working relationships with HHS Office of the CIO, NIH Office of Information Technology, and VA Office of Information Security. Those relationships do not produce special treatment, but they do produce communication efficiency: GRSi knows how the relevant AO offices receive SARs, what level of narrative depth they expect, and how to structure remediation conversations during agency review.

For CSPs sponsored by agencies outside that footprint (DoD, GSA, Treasury, Commerce), GRSi's advantage is smaller. The firm is a competent assessor in any agency context, but it does not bring the institutional familiarity that justifies a premium over equally competent alternatives. CSPs whose sponsoring agency is DoD-adjacent often pick Kratos / SecureInfo instead for the deeper DoD-context heritage.

GRSi prices in the middle of the recognized-firm range on Moderate. The firm sits above ControlCase and below Coalfire, with positioning roughly comparable to A-LIGN on like-for-like scope. The pricing reflects a federal-services delivery model that carries higher overhead than commercial-style firms but lower overhead than the largest brand-name 3PAOs.

The firm's pricing flexibility is moderate. GRSi will entertain phased scoping discussions but not as enthusiastically as A-LIGN. It will offer multi-year ConMon commitment discounts but not as aggressively as the cost-competitive mid-tier firms. The right framing for negotiation is around scope discipline and inheritance clarity rather than headline rate reduction.

Agency-relationship advantages in 3PAO selection are real but easily overstated. The advantage does not produce special treatment of the SAR; FedRAMP independence rules and PMO oversight ensure that. What it produces is communication efficiency. GRSi's assessors writing for an HHS sponsor know which narrative depth, which prose register, and which evidence presentation style that AO office is comfortable with. The SAR they produce reads to the AO office as familiar, which compresses agency review by 2 to 4 weeks compared to a SAR from an unfamiliar firm.

For CSPs racing a fiscal-year ATO target with an HHS sponsor, that 2 to 4 week compression can be the decisive factor in hitting the date. Federal fiscal-year deadlines (September 30) drive a meaningful share of FedRAMP authorization timing, and the cost of missing the date can include sponsor disengagement, budget cycle delays, and lost addressable revenue. Against that backdrop, paying the GRSi premium for review-time compression is rational economics.

For CSPs without an aggressive fiscal-year deadline, the advantage is smaller. A two-week compression in agency review on an authorization that already takes 14 to 18 months total is real but rarely decisive. For that profile, ControlCase's cost advantage or A-LIGN's flexibility advantage often produces a better overall outcome than GRSi's relationship advantage.

GRSi is not the right pick for three profiles. Early-stage startups still building security fundamentals: the firm's federal-services discipline is best deployed against mature security programs, not as a teaching environment. CSPs whose sponsoring agency is outside the firm's institutional footprint: the relationship premium is unused in that context. Multi-framework programs running PCI DSS, SOC 2, and FedRAMP in parallel: ControlCase's cross-framework efficiency or Schellman's commercial assurance cross-leverage produces better economics than GRSi's federal-services depth.

GRSi is the right pick when three conditions align: a mature security program with strong evidence discipline, a sponsoring agency in HHS / NIH / VA or a closely-related civilian footprint, and a fiscal-year deadline where agency review compression has measurable financial value. For that profile, the firm's premium is well-earned.